World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
37847
World Ranking
9580
National Ranking
934

Nigel H. Russell publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nigel H. Russell sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 647 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nigel H. Russell D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nigel H. Russell sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nigel H. Russell is affiliated with the University of Nottingham in the United Kingdom. Their research primarily focuses on Medicine, with a strong emphasis on Hematology, molecular biology, public health, genetics, and oncology. This diverse range of subfields reflects the complexity and interdisciplinary nature of their work in disease biology and treatment.

The scientist has contributed notably to several topics within hematologic malignancies and treatments. Their main areas of research include:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma Research and Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Retinoids in leukemia and cellular processes

Nigel H. Russell has a significant publication record with frequent publications in the following venues:

  • Blood
  • British Journal of Haematology
  • Blood Advances
  • HemaSphere
  • Journal of Clinical Oncology

Among their recent papers are:

  • "Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia," published in 2022 in the New England Journal of Medicine
  • "Molecular MRD status and outcome after transplantation in NPM1-mutated AML," published in 2020 in Blood
  • "Unified classification and risk-stratification in Acute Myeloid Leukemia," published in 2022 in Nature Communications
  • "The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants," published in 2020 in Nature Communications
  • "Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia," published in 2020 in British Journal of Haematology

Collaboration is an important aspect of their work. Frequent co-authors include:

  • Richard Dillon
  • Amanda Gilkes
  • Mike Dennis
  • Nicola Potter
  • Steven Knapper

This pattern of co-authorship indicates engagement with a network of researchers in similar or complementary fields. Nigel H. Russell's work spans clinical and molecular studies, contributing to understanding and developing treatments for various forms of leukemia and related hematological disorders.

Best Publications

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Assessment of Minimal Residual Disease in Standard-Risk AML.

    Adam Ivey;Robert Kerrin Hills;Michael A. Simpson;Jelena V. Jovanovic

  • Targeting FLT3 mutations in AML: review of current knowledge and evidence.

    Naval Daver;Richard F. Schlenk;Nigel H. Russell;Mark J. Levis

  • Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

    Alan Kenneth Burnett;Robert Kerrin Hills;Donald Milligan;Lars Kjeldsen

  • Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Brian A. Walker;Eileen M. Boyle;Christopher P. Wardell;Alex Murison

  • Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)

    Norbert Schmitz;Peter Dreger;Meinolf Suttorp;Ernst B. Rohwedder

  • Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

    Stephen P. Robinson;Anthony H. Goldstone;Stephen Mackinnon;Angelo Carella

  • Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

    Alan K Burnett;Nigel H Russell;Robert Kerrin Hills;David Bowen

  • Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Miguel A. Sanz;Miguel A. Sanz;Pierre Fenaux;Martin S. Tallman;Elihu H. Estey

  • Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.

    G. Gahrton;H. Svensson;M. Cavo;J. Apperley

  • The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

    Gareth J. Morgan;Walter M. Gregory;Faith E. Davies;Sue E. Bell

  • Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

    Oliver C. Goodyear;Mike Dennis;Nadira Y. Jilani;Nadira Y. Jilani;Justin Loke

  • Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

    Alan Kenneth Burnett;Nigel H. Russell;Robert Kerrin Hills;Jonathan Kell

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

    Jorge E. Cortes;Samer Khaled;Giovanni Martinelli;Alexander E. Perl

  • Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

    Alan Kenneth Burnett;Nigel H. Russell;Robert Kerrin Hills;Ann E. Hunter

  • Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Anna Sureda;Stephen Robinson;Carmen Canals;Angelo M. Carella

  • Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

    Andy C. Rawstron;Ben Kennedy;Ben Kennedy;Ben Kennedy;Paul A. S. Evans;Paul A. S. Evans;Paul A. S. Evans;Faith E. Davies;Faith E. Davies;Faith E. Davies

  • Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

    P. Ljungman;K. N. Ward;B. N. Crooks;A. Parker

Frequent Co-Authors

Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
Alan Kenneth Burnett
Alan Kenneth Burnett University of Glasgow
Charles Craddock
Charles Craddock Queen Elizabeth Hospital Birmingham
Donald Milligan
Donald Milligan University of Birmingham
Gareth J. Morgan
Gareth J. Morgan Boston University
Graham Jackson
Graham Jackson University of Newcastle Australia
Faith E. Davies
Faith E. Davies New York University Langone Medical Center
Mark T. Drayson
Mark T. Drayson University of Birmingham
Walter M Gregory
Walter M Gregory University of Leeds
David Grimwade
David Grimwade King's College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine, a wide range of online degrees and certifications can help you build a rewarding healthcare career. For those passionate about pharmaceuticals, pursuing the best online pharmacy school can lead to advanced roles in pharmacy or research, often with flexible online options for working professionals.

Technology is another growing area. Earning a health information technology online degree helps students develop crucial skills in electronic health records, data analysis, and healthcare IT compliance—opening doors to administrative or analyst positions.

Certification programs are also valuable entry points. The cheapest medical coding certification online equips students with foundational knowledge for medical billing and coding roles, which are in high demand across hospitals, clinics, and insurance companies.

Those aiming for clinical leadership can consider the cheapest fnp programs. Family Nurse Practitioners play a vital primary care role, and affordable online pathways make this advanced degree more accessible for nursing professionals.

Best Scientists Citing Nigel H. Russell

Trending Scientists